Kidney cleanse? experimental drug aims to flush cholesterol from damaged kidneys
NCT ID NCT06489340
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial planned to test an experimental drug called VAR200 (2-HPβCD) in adults with type 2 diabetes and kidney disease. The drug works by removing extra cholesterol from kidney cells, which might help protect the kidneys. However, the study was withdrawn before any participants were enrolled, so no data was collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 2-hydroxypropyl-β-cyclodextrin (2-HPβCD)
- What this could lead to
- If it worked, this could point toward a new way to slow kidney damage in people with type 2 diabetes.
- What could go wrong
- The trial was withdrawn before enrolling anyone, so no results exist. It is very early-stage and may not be safe or effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Advancement Center, PLLC
San Antonio, Texas, 78212, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test may predict rapid kidney decline in diabetes
- Blood test could flag rapid kidney failure risk in diabetes
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Could your blood type predict kidney treatment success?
- One infusion, two targets: a uric-acid-lowering drug takes aim at heart and kidney disease in youth-onset diabetes